No therapeutic area separates clinical success from reimbursement success as sharply as obesity. The incretin-based drugs (the GLP-1 class of injections and tablets) produce weight loss no payer disputes — and yet coverage remains the exception rather than the rule in many systems, because the people eligible for treatment are counted not in thousands but as a broad share of all adults. In obesity, the market access question is rarely “does it work?”; it is “who pays, for whom, and for how long?”. This page brings together MARA’s independent assessments of the field.
What payers ask before reimbursing obesity drugs
What does the budget look like at population scale?
Even conservative uptake among eligible adults produces spending few drug budgets have absorbed before. Payers respond by carving the population: BMI thresholds, comorbidity requirements, specialist-only initiation, step-through lifestyle programmes (a diet-and-exercise programme required before the drug is paid for).
Is it a “lifestyle” drug or a cardiometabolic one?
Several systems have long-standing rules against reimbursing weight-loss medicines — Germany’s statutory exclusion is the clearest example, and US Medicare’s ran the same way until 2026, when a time-limited federal demonstration began covering leading obesity drugs at negotiated prices while the exclusion itself remains law. Outcomes evidence beyond weight, above all cardiovascular results, is what moves a drug from one category to the other in payers’ — and lawmakers’ — eyes.
What happens when patients stop?
Discontinuation is common, weight returns, and payers increasingly ask for stopping rules and persistence data before committing to open-ended coverage.
How does price competition change the picture?
Oral small molecules, new combinations and supply dynamics keep shifting the comparator landscape faster than HTA (health technology assessment — the formal evaluation of a drug’s value) cycles normally move.
The MARA record in obesity
In obesity the evidence ages faster than almost anywhere else in the MARA catalogue — head-to-head data, outcomes trials and new oral competitors keep re-opening settled questions. That is why several drugs below carry more than one vintage: re-assessing a drug matters as much here as assessing a new one, and the dated record shows how the reimbursement picture has shifted. Each report answers the same set of payer questions, carries its “as of” date, and stays on the record: a newer vintage replaces an older one visibly, never silently. Assessments are produced on MARA’s own initiative for awareness; the current MARA Rating for any drug is available on request.
Current assessments
- Foundayo / orforglipron for managing overweight and obesity as of June 2026
- Wegovy / semaglutide for weight Management in Adults With Obesity or Overweight and at Least One Weight-Related Comorbidity as of June 2026
- Cagrilintide and semaglutide (cagrisema) for treating Obesity and Overweight With Obesity-Related Comorbidities as of February 2026
- Retatrutide for the treatment of obesity as of January 2026
- Tirzepatide for managing overweight and obesity as of September 2025
- Survodutide for obesity treatment as of July 2025
- Retatrutide for obesity ± Metabolic Disorders as of July 2025
- Orforglipron for obesity and Type 2 Diabetes as of July 2025
- Cagrilintide-semaglutide for treating obesity with or without type 2 diabetes as of July 2025
- Wegovy / semaglutide for managing overweight and obesity as of September 2023
Earlier assessments (each replaced by a newer version)
Same molecules, different questions
Reimbursement risk is asked and answered per indication. MARA assesses the same molecules separately where the payer question differs: tirzepatide in type 2 diabetes (the Mounjaro rating, and an earlier 2023 vintage) and semaglutide in MASH, a liver disease.
Selected commentary
For how a MARA Rating is built, see the methodology and what a MARA Rating is. To request the current rating for any drug in this area, use the contact form.